Private Equity
Location
Rotterdam, The Netherlands
Boston, MA, USA
Private Equity
All Portfolio items
See full Private Equity portfolio
Viroclinics Biosciences is a leader in diagnostic and clinical-trial services. It is one of the few labs in the world able to perform highly complex, specialized diagnostic and preclinical studies in the field of virology. Viroclinics operates globally as the preferred virology testing laboratory for top-ten biopharmaceutical companies.
Gilde acquired a majority share in 2013. During Gilde ownership Viroclinics developed new services for the biopharmaceutical industry, expanded its facilities and tripled its revenues. Viroclinics was sold in 2017 to Parcom Capital.
More Viroclinics Biosciences news
d3 Medicine LLC and Viroclinics Biosciences BV form virology drug development alliance to serve the
Gilde Healthcare Services acquires majority share in Viroclinics Biosciences from Erasmus MC
Private Equity
Klifo
KLIFO is a leading drug development consultancy headquartered in Copenhagen with extensive experience in partnering with biotech and pharmaceutical companies to advance their drug development projects. The company is a leader in the Scandinavian market and has operations in Germany
Private Equity
Synexa Life Sciences
Synexa Life Sciences is an industry leader in contract bioanalytics and biomarker research services specializing in biopharmaceuticals. It delivers bespoke bioanalytical solutions to meet its global clients’ specific challenges and clinical milestones. Founded in 2003 as an early pioneer in
Private Equity
Essange Reagents
Essange Reagents is an international developer and manufacturer of in vitro diagnostics (IVD) reagents with an extensive product portfolio of hematology and immune reagents. Owing to its extensive history in blood research, Essange Reagents stands out in the healthcare landscape,
